Gelonghui November 1 | Dahua Jixian published a report that Sinopharm Holdings' revenue for the first nine months increased 9.7% year-on-year to 445.9 billion yuan, and net profit increased 4.1% year-on-year to 6.1 billion yuan, lower than the bank's and market expectations. The report quoted management's expectation that revenue will maintain steady expansion this year, and emerging businesses will become the driving force for new growth; the company will also continue to improve its cash flow management. The bank lowered Sinopharm's revenue growth forecast for each year from 2023 to 25 to 9.6%, 9.2% and 9.1% respectively, and lowered its target price from HK$30 to HK$25, maintaining its rating as “buy”.